WO2017147316A1 - Synthetic processes and intermediates - Google Patents

Synthetic processes and intermediates Download PDF

Info

Publication number
WO2017147316A1
WO2017147316A1 PCT/US2017/019161 US2017019161W WO2017147316A1 WO 2017147316 A1 WO2017147316 A1 WO 2017147316A1 US 2017019161 W US2017019161 W US 2017019161W WO 2017147316 A1 WO2017147316 A1 WO 2017147316A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
preparing
reaction
range
Prior art date
Application number
PCT/US2017/019161
Other languages
French (fr)
Inventor
Ravi Ponnaiah
Sudhakar Sunkari
Anil Kumar Soni
Siva Rami Reddy ATHUNURI
Thrisulapani KORRAKUTI
Pullarao SEELAM
Ajit S. PARHI
Original Assignee
Taxis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taxis Pharmaceuticals, Inc. filed Critical Taxis Pharmaceuticals, Inc.
Priority to EP17757224.5A priority Critical patent/EP3419967A4/en
Priority to US16/079,469 priority patent/US10513528B2/en
Priority to JP2018563759A priority patent/JP2019507801A/en
Priority to CA3015768A priority patent/CA3015768A1/en
Priority to CN201780022884.2A priority patent/CN109195957A/en
Publication of WO2017147316A1 publication Critical patent/WO2017147316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Definitions

  • the invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I) or a salt thereof. These processes and intermediates allow commercial quantities of the compound to be prepared in a cost effective and enviommentally acceptable manner. Accordingly, these processes and intermediates will facilitate the commercial development of the compound of formula (I).
  • the invention provides a method for preparing an amino pyridine of formula g by converting a corresponding nitro pyridine of formula f: f
  • the invention provides a method for preparing a nitro pyridine of formula f by reacting 2-chloro-3-nitro-5-(trifluoromethyl)pyridine with thiourea to provide the nitro pyridine of formula f.
  • the invention provides a method for preparing an amide of formula c by converting an acid of formula b: to the amide of formula c.
  • the invention provides a method for preparing a compound of formula a by converting a 2,4-difluorophenol to the compound of formula a.
  • the invention provides a method for preparing a compound of formula (I):
  • Figure 1 illustrates synthetic routes of the invention and synthetic intermediates of the invention.
  • FIG. 2 illustrates synthetic routes of the invention and synthetic intermediates of the invention.
  • the invention provides a method for preparing a compound of formula (I):
  • the reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35°C in a polar solvent.
  • Suitable solvents include polar solvents (e.g. DMF or DMSO) and mixtures thereof.
  • Suitable bases include inorganic bases, such as hindered bases (e.g. Potassium carbonate, sodium carbonate).
  • use acid include methane sulfonic acid, oxalic acid and tartaric acid.
  • the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35°C.
  • the reaction can typically be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 45 °C to about 60 °C in a polar solvent.
  • Suitable solvents include ethyl acetate, chlorinated hydrocarbons (e.g.
  • reaction can be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 45 °C to about 60°C.
  • the reaction can typically be carried out at a temperature in the range of about 65°C to about 70 °C or in the range of about 60°C to about 80°C in a polar solvent.
  • Suitable solvents include ethyl acetate and mixtures thereof.
  • Suitable reducing agents include iron/acetic acid, zinc/ammonium chloride.
  • the reaction can be carried out at a temperature in the range of about 65°C to about 70 °C or in the range of about 60 °C to about 80 °C.
  • the invention provides a method for preparing a nitro pyridine of formula f by reacting 2-chloro-3-nitro-5-(trifuoromethyl)pyridine with thiourea to provide the nitro pyridine of formula f.
  • the reaction can typically be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 40 °C to about 60 °C in a protic solvent.
  • Suitable solvents include protic solvent (e.g. methanol, isopropyl alcohol or ethanol), and mixtures thereof.
  • the reaction can be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 40 °C to about 60 °C.
  • the reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35 °C in a polar solvent.
  • Suitable solvents include polar solvents (e.g. DMF or DMSO), protic solvents (e.g. methanol, ethanol) and mixtures thereof.
  • Suitable reducing reagents include Pd/C, Pd(OH) 2 and eerie ammonium nitrate.
  • the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35 °C.
  • the reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 0 °C to about 35 °C in a polar solvent.
  • Suitable solvents include hydrocarbons (e.g. THF), polar solvents (e.g. DMF, DMSO), and mixtures thereof.
  • Suitable bases include inorganic bases (e.g. NaH).
  • the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 0 °C to about 35 °C.
  • the reaction can typically be carried out at a temperature in the range of about -75 °C to about 0 °C or in the range of about -80 °C to about 0 °C in a polar solvent.
  • Suitable solvents include ethers (e.g. THF, diethyl ether and MTBE), and mixtures thereof.
  • Suitable bases include n-BuLi.
  • the reaction can be carried out at a temperature in the range of about -75 °C to about 0 °C or in the range of about -80 °C to about 0 °C.
  • the reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 oC to about 40 °C in a polar solvent.
  • Suitable solvents include polar solvents (e.g. DMF, THF), and mixtures thereof.
  • Suitable bases include aqueous ammonia.
  • the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 40 °C.
  • the invention provides a method for preparing a compound of formula a by converting a 2,4-difluorophenol to the compound of formula a.
  • the reaction can typically be carried out at a temperature in the range of about 55 °C to about 60°C or in the range of about 40 °C to about 65 °C in a polar solvent.
  • Suitable solvents include polar solvents (e.g. acetone, acetonitrile), protic solvents (e.g. methanol, ethanol) and mixtures thereof.
  • Suitable bases include inorganic bases such as potassium carbonate, sodium carbonate.
  • the reaction can be carried out at a temperature in the range of about 55 °C to about 60°C or in the range of about 40 °C to about 65 °C.
  • the invention provides a method for preparing a compound of formula (I):
  • reaction comprising reacting an amide of formula j: with an acid chloride of formula: to provide the compound of formula (I).
  • the reaction can typically be carried out at a temperature in the range of about 0 °C-50 °C in a polar solvent.
  • Suitable solvents include THF,
  • Suitable bases include amine bases, such as hindered amine bases (e.g. N,N-diisopropyl-N-ethylamine), inorganic bases such as NaH, KH,
  • reaction can be carried out at a temperature in the range of about 0 °C-rt in DMF with NaH as base.
  • the reaction can typically be carried out at a temperature in the range of about 45 °C to about 50 °C or in the range of about 40 °C to about 60 °C in a polar solvent.
  • Suitable solvents include polar solvents (e.g. DMF, THF) and mixtures thereof.
  • Suitable bases include inorganic bases, such as sodium bicarbonate.
  • the reaction can be carried out at a temperature in the range of about 45 °C to about 50 °C or in the range of about 40 °C to about 60 °C.
  • TXA709. Mesylate The TXA709 free base was dissolved in THF (1.5L, 7.5 vol) and added Methane sulfonic acid (66g, 686.78 mmol) at 35-40 °C. The contents were stirred for 16h at 25-30 °C, cooled to 0-5 °C and stirred for lh and filtered to give crude as brown solid. Purification of TXA709 Mesylate: To the solution of crude (TXA709 free base) dissolved in Acetone: Methanol (5.5: 7.0) mixture (2.5L, 12.5 vol) at 55-65 °C, activated carbon (0.5g) was added, stirred for 15 min and filtered through Hyflo in hot condition.
  • reaction conversion by HPLC. After the reaction completion, reaction mixture mass was quenched with IN HC1 and adjust the PH to 7.0 to 7.5. The precipitated solid was filtered and washed with water to give a brown solid. The crude solid obtained was purified with water (2.0L, 10 vol.) and dried for 18h at 60-65 °C.
  • reaction mixture was cooled to 25-30 °C & Ethyl acetate (1050 mL, 3.0 vo.) & water (1050 mL, 3.0 vol.) was added.
  • the reaction mass was filtered through Hyflo bed and the layers were separated.
  • the combined organic layer was washed with sodium bicarbonate, Water and sat. NaCl solution and the layers were separated.
  • the organic layer was concentrated and the product was precipitated by using MDC (2 L, 5 vol) at 5-10 °C.
  • the solid isolated was filtered & dried to give final product as brown solid. (255.0g, 84.15% yield).
  • TXA709. Mesylate The TXA709 free base was dissolved in THF (1.5L, 7.5 vol) and added Methane sulfonic acid (66g, 686.78 mmol) at 35-40 °C. The contents were stirred for 16h at 25-30 °C, cooled to 0-5 °C and stirred for lh and filtered to give crude as brown solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I): or a salt thereof.

Description

SYNTHETIC PROCESSES AND INTERMEDIATES
Related Applications
This application claims priority to Indian Application No. 201641006639 filed on
25 February 2016. The entire contents of the foregoing are incorporated herein by
reference.
Background of the Invention
International Patent Application Publication Number WO 2014/074932 reports a series of soluable compounds that are useful as antibiotic agents. One of these compounds, the compound of formula (I):
Figure imgf000003_0001
is currently being evaluated for potential use as an antibacterial agent in humans.
Currently there is a need for improved synthetic processes and new synthetic intermediates that can be used to prepare commercial quantities of the compound of formula (I).
Summary of the Invention
The invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I) or a salt thereof. These processes and intermediates allow commercial quantities of the compound to be prepared in a cost effective and enviommentally acceptable manner. Accordingly, these processes and intermediates will facilitate the commercial development of the compound of formula (I).
In one embodiment the invention provides a method for preparing a compound of formula
(I):
Figure imgf000003_0002
comprising reacting a phenol of formula e:
Figure imgf000004_0001
with a chloride of formula h:
Figure imgf000004_0002
to provide the compound of formula (I).
In one embodiment the invention provides a method for preparing a chloride of formula h
by reacting the amino pyridine of formul
with chloroacetic acid:
Figure imgf000004_0003
to provide the chloride of formula h.
In one embodiment the invention provides a method for preparing an amino pyridine of formula g by converting a corresponding nitro pyridine of formula f:
Figure imgf000004_0004
f
to the amino pyridine of formula g.
In one embodiment the invention provides a method for preparing a nitro pyridine of formula f by reacting 2-chloro-3-nitro-5-(trifluoromethyl)pyridine with thiourea to provide the nitro pyridine of formula f.
In one embodiment the invention provides a method for preparing a phenol of formula e
Figure imgf000004_0005
Comprising deprotecting the corresponding benzyl ether of formula d:
Figure imgf000005_0001
to provide the phenol of formula e.
In one embodiment the invention provides a method for preparing a benzyl ether of formula d:
Figure imgf000005_0002
by coupling an acid chloride of formula i or a salt thereof:
Figure imgf000005_0003
with an amide of formula c:
Figure imgf000005_0004
to provide the benzyl ether of formula d.
In one embodiment the invention provides a method for preparing an amide of formula c by converting an acid of formula b:
Figure imgf000006_0001
to the amide of formula c.
In one embodiment the invention provides a method for preparing an acid of formula b by converting a compound of formula a:
Figure imgf000006_0002
to the acid of formula b.
In one embodiment the invention provides a method for preparing a compound of formula a by converting a 2,4-difluorophenol to the compound of formula a.
In one embodiment the invention provides a method for preparing a compound of formula (I):
Figure imgf000006_0003
comprising reacting a phenol of formula j:
Figure imgf000006_0004
with an acid chloride of formula:
Figure imgf000007_0001
to provide the compound of formula (I).
In one embodiment the invention provides a method for preparing a compound of formula j :
Figure imgf000007_0002
comprising reacting a chloride of formula h:
Figure imgf000007_0003
with a compound of formula:
Figure imgf000007_0004
to provide the compound of formula j.
In one embodiment the invention provides a compound selected from:
Figure imgf000007_0005
a b c
Figure imgf000008_0001
and salts thereof.
Brief Description of the Figures
Figure 1 illustrates synthetic routes of the invention and synthetic intermediates of the invention.
Figure 2 illustrates synthetic routes of the invention and synthetic intermediates of the invention.
Detailed Description
embodiment the invention provides a method for preparing a compound of formula (I):
Figure imgf000008_0002
comprising reacting a phenol of formula e:
Figure imgf000008_0003
with a chloride of formula h:
Figure imgf000008_0004
to provide the compound of formula (I). The reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35°C in a polar solvent. Suitable solvents include polar solvents (e.g. DMF or DMSO) and mixtures thereof. Suitable bases include inorganic bases, such as hindered bases (e.g. Potassium carbonate, sodium carbonate). For the salt preparation, use acid include methane sulfonic acid, oxalic acid and tartaric acid. In one embodiment the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35°C.
In one embodiment the invention provides a method for preparing a chloride of formula h by reacting the amino pyridine of formula g:
Figure imgf000009_0001
with chloroacetic acid:
O
HO
to provide the chloride of formula h. The reaction can typically be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 45 °C to about 60 °C in a polar solvent. Suitable solvents include ethyl acetate, chlorinated hydrocarbons (e.g.
dichloromethane), and aromatic hydrocarbons (e.g. toluene), and mixtures thereof. In one embodiment the reaction can be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 45 °C to about 60°C.
In one embodiment the invention provides a method for preparing an amino pyridine of formula g by converting a corresponding nitro pyridine of formula f:
Figure imgf000009_0002
to the amino pyridine of formula g. The reaction can typically be carried out at a temperature in the range of about 65°C to about 70 °C or in the range of about 60°C to about 80°C in a polar solvent. Suitable solvents include ethyl acetate and mixtures thereof. Suitable reducing agents include iron/acetic acid, zinc/ammonium chloride. In one embodiment the reaction can be carried out at a temperature in the range of about 65°C to about 70 °C or in the range of about 60 °C to about 80 °C.
In one embodiment the invention provides a method for preparing a nitro pyridine of formula f by reacting 2-chloro-3-nitro-5-(trifuoromethyl)pyridine with thiourea to provide the nitro pyridine of formula f. The reaction can typically be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 40 °C to about 60 °C in a protic solvent. Suitable solvents include protic solvent (e.g. methanol, isopropyl alcohol or ethanol), and mixtures thereof. In one embodiment the reaction can be carried out at a temperature in the range of about 50 °C to about 55 °C or in the range of about 40 °C to about 60 °C.
In one embodiment the invention provides a method for preparing a phenol of formula e:
Figure imgf000010_0001
comprising de-protecting the corresponding benzyl ether of formula d:
Figure imgf000010_0002
to provide the phenol of formula e. The reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35 °C in a polar solvent. Suitable solvents include polar solvents (e.g. DMF or DMSO), protic solvents (e.g. methanol, ethanol) and mixtures thereof. Suitable reducing reagents include Pd/C, Pd(OH)2 and eerie ammonium nitrate. In one embodiment the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 35 °C.
In one embodiment the invention provides a method for preparing a benzyl ether of formula d:
Figure imgf000010_0003
by coupling an acid chloride of formula i or a salt thereof:
Figure imgf000010_0004
with an amide of formula c:
Figure imgf000011_0001
to provide the benzyl ether of formula d. The reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 0 °C to about 35 °C in a polar solvent. Suitable solvents include hydrocarbons (e.g. THF), polar solvents (e.g. DMF, DMSO), and mixtures thereof. Suitable bases include inorganic bases (e.g. NaH). In one embodiment the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 0 °C to about 35 °C.
In one embodiment the invention provides a method for preparing an amide of formula c by converting an acid of formula b:
Figure imgf000011_0002
b
to the amide of formula c. The reaction can typically be carried out at a temperature in the range of about -75 °C to about 0 °C or in the range of about -80 °C to about 0 °C in a polar solvent. Suitable solvents include ethers (e.g. THF, diethyl ether and MTBE), and mixtures thereof. Suitable bases include n-BuLi. In one embodiment the reaction can be carried out at a temperature in the range of about -75 °C to about 0 °C or in the range of about -80 °C to about 0 °C.
In one embodiment the invention provides a method for preparing an acid of formula b by converting a compound of formula a:
Figure imgf000012_0001
to the acid of formula b. The reaction can typically be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 oC to about 40 °C in a polar solvent. Suitable solvents include polar solvents (e.g. DMF, THF), and mixtures thereof. Suitable bases include aqueous ammonia. In one embodiment the reaction can be carried out at a temperature in the range of about 25 °C to about 30 °C or in the range of about 20 °C to about 40 °C.
In one embodiment the invention provides a method for preparing a compound of formula a by converting a 2,4-difluorophenol to the compound of formula a. The reaction can typically be carried out at a temperature in the range of about 55 °C to about 60°C or in the range of about 40 °C to about 65 °C in a polar solvent. Suitable solvents include polar solvents (e.g. acetone, acetonitrile), protic solvents (e.g. methanol, ethanol) and mixtures thereof.
Suitable bases include inorganic bases such as potassium carbonate, sodium carbonate. In one embodiment the reaction can be carried out at a temperature in the range of about 55 °C to about 60°C or in the range of about 40 °C to about 65 °C. In one embodiment the invention provides a method for preparing a compound of formula (I):
Figure imgf000012_0002
comprising reacting an amide of formula j:
Figure imgf000012_0003
with an acid chloride of formula:
Figure imgf000012_0004
to provide the compound of formula (I). The reaction can typically be carried out at a temperature in the range of about 0 °C-50 °C in a polar solvent. Suitable solvents include THF,
DMF, ACN, DMSO, and mixtures thereof. Suitable bases include amine bases, such as hindered amine bases (e.g. N,N-diisopropyl-N-ethylamine), inorganic bases such as NaH, KH,
NaOH, KOH, NaOTiu In one embodiment the reaction can be carried out at a temperature in the range of about 0 °C-rt in DMF with NaH as base.
In one embodiment the invention provides a method for preparing a compound of formula j:
Figure imgf000013_0001
comprising reacting a chloride of formula h:
Figure imgf000013_0002
with a compound of formula:
Figure imgf000013_0003
to provide the compound of formula j. The reaction can typically be carried out at a temperature in the range of about 45 °C to about 50 °C or in the range of about 40 °C to about 60 °C in a polar solvent. Suitable solvents include polar solvents (e.g. DMF, THF) and mixtures thereof.
Suitable bases include inorganic bases, such as sodium bicarbonate. In one embodiment the reaction can be carried out at a temperature in the range of about 45 °C to about 50 °C or in the range of about 40 °C to about 60 °C.
The invention will now be illustrated by the following non-limiting examples. EXAMPLES
Example 1 Preparation of Compound
Figure imgf000014_0001
Preparation of TXA709. Mesylate: The TXA709 free base was dissolved in THF (1.5L, 7.5 vol) and added Methane sulfonic acid (66g, 686.78 mmol) at 35-40 °C. The contents were stirred for 16h at 25-30 °C, cooled to 0-5 °C and stirred for lh and filtered to give crude as brown solid. Purification of TXA709 Mesylate: To the solution of crude (TXA709 free base) dissolved in Acetone: Methanol (5.5: 7.0) mixture (2.5L, 12.5 vol) at 55-65 °C, activated carbon (0.5g) was added, stirred for 15 min and filtered through Hyflo in hot condition. The filtrate was cooled to 25-30 °C, followed by further cooling to 0-5 °C. The contents were stirred for 2h, filtered and dried at 50-55 °C for 8h to give pure product of TXA709. Mesylate as light brown solid. (1 14. Og, 27.89% yield). Ή NMR (300 MHz, DMSO-d6) δ: 11.74 (bs, 1H), 9.07 (s, 1H), 8.95 (s, 1H),
7.50-7.58 (m, 1 H), 7.17-7.24 (m, 1H), 5.81 (s, 2H), 3.45 - 3.50 (d, 2H), 2.91 -3.02 (m, 2H), 2.77- 2.84 (d, 4H), 2..31 (s,3H), 2.04 - 2.08 (d, 2H), 1.65-1.77 (m, 2H). MS: 515.08 (M+l).
Preparation of TXA709. Free base: To a 10 L 4-neck round bottom flask equipped with a mechanical stirrer, charged N-[(2,6-Difluoro-3-hydroxyphenyl)carbonyl]-l -methyl piperidine-4- carboxamide (200g, 670.49 mmol), DMF (5.0 L, 25 vol.), Potassium carbonate (102g, 738.06 mmol) and 2-(Chloromethyl)-6-(trifluoromethyl)[l ,3]thiazolo[5,4-i]pyridine (254g. 1005.38 mmol.) under nitrogen atmosphere. The reaction mixture was stirred for 6h at 25-30 °C.
Monitored the reaction conversion by HPLC. After the reaction completion, reaction mixture mass was quenched with IN HC1 and adjust the PH to 7.0 to 7.5. The precipitated solid was filtered and washed with water to give a brown solid. The crude solid obtained was purified with water (2.0L, 10 vol.) and dried for 18h at 60-65 °C.
The intermediate compound 7V-[(2,6-Difluoro-3-hydroxyphenyl)carbonyl]-l- methylpiperidine -4-carboxamide used in Example 1 was prepared as follows. a. Preparation of l-(Benzyloxy)-2,4-difluorobenzene
Figure imgf000015_0001
To a 5.0 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 2,4-Difluorophenol (500g, 3843.49 mmol), Benzyl bromide (665g, 3880 mmol), Potassium carbonate (635g, 4590 mmol) and Acetone (3000 mL, 6.0 vol.) at 25-30 °C. The contents were stirred for lh at 55-60 °C. The reaction completion was monitored by HPLC After completion of the reaction, distilled the acetone completely at below 50 °C and cooled to 25-30 °C. Water (5.0 L, 10.0 vol.) was added slowly at 25-30 °C and further cooled to 0-10 °C. The contents were stirred for lh and the solid was filtered & dried to give a crude solid. The crude was washed with water (2.5 L, 5.0 vol.) and 10% Isopropyl alcohol: Water Mixture (2.5 L, 5.0 vol.) at 25-30 °C & dried at 30-35 °C under reduced pressure for 8h to give pure product as white solid (805g, 95.26% yield). 1H NMR (300 MHz, DMSO-d6) δ: 7.23-7.47 (m, 7H), 6.97-7.05 (m, H), 5.16 (s, 2H).
Preparation of 3-(Benzyloxy)-2, -difluorobenzoicacid
Figure imgf000015_0002
To a 20 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged THF (7.9L, 10.0 vol.) and Di-isopropyl amine (474g, 4680 mmol) under nitrogen atmosphere. The reaction mixture was cooled to 0 to -10 °C, n-BuLi (1.6 M Solution in Hexane) (2.7L, 4310 mmol.) was added slowly and stirred the mixture for lh at 0 to -10 °C. The contents were cooled to -60 to -75 °C, l-(Benzyloxy)-2,4-difluorobenzene (790g) solution in THF (3.95L, 5.0 vo.) was added slowly drop wise at -60 to -75 °C and stirred for lh. Dry C02 gas was purged into the reaction mixture for 1.5 h at -55 to -75 °C. The reaction completion was monitored by TLC. After reaction completion, the mass temperature raised to 0-20 °C and the pH 0-2 was adjusted with aqueous HC1 solution (3.16L, 4.0 vol.) water (2.4 L, 3.0 vol.) was added. The layers separated and aqueous layer was extracted with MDC. The organic layers combined and concentrated at below 50 °C under reduced pressure to give crude solid. The obtained crude was further purified by using base-acid treatment with 10% NaOH solution and followed by washing with 10% Ethyl acetate: Cyclohexane mixture (2.7L, 3.7 vol.), filtered the product and dried at 60-65 °C for 8h to give a pure product as white solid. (814g, 85.86% yield). ]H NMR (300 MHz, DMSO-d6) 5: 13.98 (bs, 1H), 7.33-7.47 (m, 6H), 7.10-716 (m, 1H), 5.20 (s, 2H). MS: 265.12 (M+l). c. Preparation of 3-(Benzyloxy)-2, -difluorobenzamide
Figure imgf000016_0001
To a 10 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 3- (Benzyloxy)-2,6-difluorobenzoicacid (800g, 3027.66 mmol), DMF (80.0 mL, 0.10 vol.) and dry THF (2.4 L, 3.0 vol.) under nitrogen atmosphere. Thionyl chloride (540g, 4538.95 mmol) was added slowly at 25-30 °C. The reaction mixture was stirred for 4h at 25-30 °C. The reaction completion was monitored by TLC. After reaction completion, the reaction mixture was quenched in aqueous ammonia solution (8.0L, 10 vol.) at below 20 °C and stirred for 2h. The THF solvent was distilled completely at below 50 °C under reduced pressure. The precipitated solid was filtered & washed with water to give crude solid. The crude was purified by using 10% Ethylacetate: Cyclohexane (2.4L, 3.0 vo.) mixture and dried at 60-65 °C for 8h to give pure product as white solid. (735g, 92.8% yield). 1H NMR (300 MHz, DMSO-d6) δ: 8.14 (bs, 1H), 7.85 (bs, 1H), 7.25-7.47 (m, 6H), 7.03-7.09 (m, 1H), 5.15 (s, 2H). d. Preparation of 7V-{[3-(Benzyloxy)-2,6-difluorophenyI]carbonyI}-l-methylpiperdine- 4-carboxamide
Figure imgf000017_0001
To a 20 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 3-
(Benzyloxy)-2, 6-difluorobenzamide (733g, 2784.4 mmol) and THF (7.33 L, 10.0 vol.) under nitrogen atmosphere. The contents were stirred for 10 min and cooled to 0-5 °C, Sodium hydride (141.7 g, 5872.55 mmol, 60% dispersion in mineral oil) was added portion wise over 15 min at 0-10 °C. Later N-Methylpiperdine acid chloride.HCl (2.0 eq.) was added slowly at 0-20 °C portion-wise and stirred for 30 min. The resulting mixture was stirred for 4h at 25-30 °C. The reaction completion was monitored by HPLC. After reaction completion, the contents were cooled to 0-5 °C, water (7.3L, 10.0 vol.) was added slowly at 0-10 °C and adjust the pH 1.0-2.0 with 1 :1 aqueous HC1 solution (2.2 L, 3.0 vol.) at 0-10 °C. The layers were separated and the aqueous layer was washed with ethyl acetate (6.6L, 9.0 vol.) and concentrated the organic volatiles under reduced pressure at below 50 °C. Finally the solid was isolated by adjusting the pH 8.0-8.5 with 20% aqueous Na2C03 solution at 25-30 °C. The precipitated solid was filtered and washed with water to give final product as a white solid. (740g, 68.42% yield). 1H NMR (300 MHz, DMSO-d6) δ: 1 1.48 (bs, 1H), 7.33-7.47 (m, 6H), 7.1 1-7.14 (m, 1H), 5.19 (s, 2H), 2.74-2.78 (d, 2H), 2.50-2.51 (m, 1H), 2.13 (s, 3H), 1.72-1.87 (m, 4H), 1.48-1.53 (m, 2H). e. Preparation of N-[(2,6-Difluoro-3-hydroxyphenyI)carbonyl]-l-methylpiperidine-4- carboxamide
Figure imgf000017_0002
To a 5 L autoclave, charged N-{[3-(Benzyloxy)-2,6-difluorophenyl]carbonyl}-l-mei piperdine-4-carboxamide (350 g, 901.08 mmol), DMF (1.75 L, 10.0 vol.) and 5% wet Pd/C (52.5g, 15%w/w) with Hydrogen pressure -0.5 Kg/Cm2. The reaction mixture was stirred for lh at 25-30 °C. The reaction completion was monitored by HPLC. After completion, reaction mixture was filtered through Hy-flo and cooled to 0-5 °C. Water (8.4 L, 24.0 vol.) was added slowly to the reaction mixture at below 15 °C and the precipitated solid was filtered & dried for 8h at 60-65 °C to give pure product as brown solid. (210.Og, 78.36%). 1H NMR (300 MHz, DMSO-d6) δ: 1 1.41 (bs, 1H), 6.92-6.95 (m, 2H), 2.73-2.79 (m, 2H), 2.39-2.44 (m, 1H), 2.14 (s, 3H), 1.73-1.87 (m, 4H), 1.53-1.57 (m, 2H). MS: 299.25 (M+l).
The intermediate compound 2-(chloromethyl)-6-(trifluoromethyl)[l ,3]thiazolo[5,4- frjpyridine used in Example lwas prepared as follows. f. Preparation of 3-Nitro-2-thio-5-(trifluoromethyI)pyridine
Figure imgf000018_0001
To a 5.0L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 2- Chloro-3-nitro-5-(trifluoromethyl)pyridine (400g, 1765.69 mmol), Methanol (2.4L, 6.0 vol.) and Thiourea (150.0g, 1970 mmol) at 25-30 °C. The reaction mixture was stirred for 4h at 50-55 °C. The reaction completion was monitored by HPLC. After completion, methanol from the reaction mixture was distilled out completely under reduced pressure at below 45 °C. Water (2.0L, 5.0 vol.) was added to the reaction mixture at 25-30 °C and followed by aqueous NaOH solution added slowly at 25-30 °C. The aqueous layer was washed with Toluene and the product was precipitated by adjusting the pH 1-2 with 1 : 1 HC1 solution at 0-5 °C. The precipitate product was collected was filtered & dried to give the product as brown solid in good yield. (356.0g, 90% yield). 1H NMR (300 MHz, DMSO-d6) δ: 14.99 (bs, 1H,), 8.56-8.57 (s, 1H), 8.37 (s, 1H). MS: 223.13 (M-l).
Preparation of 3-Amino-2-thio-5-(trifluoromethyl)pyridme
Figure imgf000018_0002
To a 5.0L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 3 Nitro-2-thio-5-(trifluoromethyl)pyridine (350g, 1562.5 mmol), Iron powder (261.8g, 4687.55 mmol), Ethylacetate (910 mL, 2.6 vol.) and water (910 mL, 2.6vol.). Acetic acid (910 mL, 2.6 vol.) was added slowly at 25-30 °C. The reaction mixture was stirred for lh at 65-70 °C. The reaction completion was monitored by HPLC. After reaction completion, the reaction mixture was cooled to 25-30 °C & Ethyl acetate (1050 mL, 3.0 vo.) & water (1050 mL, 3.0 vol.) was added. The reaction mass was filtered through Hyflo bed and the layers were separated. The combined organic layer was washed with sodium bicarbonate, Water and sat. NaCl solution and the layers were separated. The organic layer was concentrated and the product was precipitated by using MDC (2 L, 5 vol) at 5-10 °C. The solid isolated was filtered & dried to give final product as brown solid. (255.0g, 84.15% yield). 1H NMR (300 MHz, DMSO-d6) δ: 13.85 (bs, 1H), 7.41 (s, 1H), 6.82-6.83 (s, 1H), 6.16 (s, 2H). MS: 195.08 (M+l).
h. Preparation of 2-(Chloromet -6-(trifluoromethyl) [ 1 ,3] thiazolo [5,4-6] pyridine
Figure imgf000019_0001
To a 5.0 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged 3- Amino-2-thio-5-(trifluoromethyl)pyridine (245g, 102.9 mmol) and Ethyl acetate (3.68L, 15 vol.) at 25-30 °C. The contents were cooled to 10-15 °C and Chloroacetyl chloride (287g, 2542 mmol) was added slowly to the reaction mixture at 10-15 °C. The reaction mixture was stirred for 15h at 50-55 °C. The reaction completion was monitored by HPLC. After reaction completion, water (1.225L, 5.0 vol) was added slowly at 25-30 °C. The organic layer was separated and washed with sodium bicarbonate, Water and sat. NaCl solution. The organic layer was concentrated & co-distilled with Isopropyl alcohol. The product was washed with Isopropyl alcohol (735 mL, 3.0 vol.) at 5-10 °C, filtered & dried to give final product as brown solid. (265g, 83.15% yield). 1H NMR (300 MHz, CDC13) δ: 8.88 (s, 1H), 8.47-8.48 (s, 1H), 4.96 (s, 2H). MS: 252.99 (M+l). The intermediate compound N-methylpiperdine-4-carbonylchloride used in step d above was prepared as follows. Preparation of N-Methylpiperdine-4-carbonylchloride
Figure imgf000020_0001
To a 1.0 L 4-neck round bottom flask equipped with a mechanical stirrer, was charged Thionyl chloride (300 mL, 3.0 vol.), N-Methylpiperdine acid .HC1 (lOOg, 556.6 mmol) under nitrogen atmosphere. The reaction mixture was heated for lh at 65-75 °C. After the reaction completion the thionyl chloride was distilled out completely and co-distilled with Cyclohexane. Finally the product was washed with Cyclohexane, filtered and dried under nitrogen atmosphere as HC1 salt (lOlg, 92% yield). Example 2 Preparation of Compound 1
Figure imgf000020_0002
To a 100-mL round bottom flask equipped with a magnetic stirrer was charged with
Compound J (1.0 g, 2.57 mmol, Compound 6 (1.0 g, 5.05 mmol), and THF (20 mL). With stirring NaH (600 mg, 15 mmol, 60% dispersion in mineral oil) was added portion wisely over 5 min. The resulting reaction mixture was stirred for 10 minutes, then a solution of water (40 μΐ) in THF (2 mL) was added via a pipet over 5 min. The reaction mixture changed from suspension to a brown solution. After completion of the reaction, it was quenched by the addition of few drops of water, and diluted with dichloromethane. The organic phase was separated, washed with brine and dried over Na2S04. The solvent was removed in vacuo, and the resulting residue was purified by ISCO using 10 % MeOH in DCM + 1% NH40H to afford a light brown solid, which was triturated with EtOAc to give a beige solid (590 mg, 44% Yield). 1H NMR (300 MHz, CDC13) δ: 8.58 (s, 1H), 8.31 (broad s, 1H), 8.24 (s, 1H), 7.24-7.14 (m, 1H), 6.94-6.87 (m, 1H), 5.50 (s, 2H), 2.94-2.80 (m, 3H), 2.28 (s, 3H), 2.10-1.74 (m, 6H). 13C NMR (100 MHz, DMSO-d6) 6 174.9, 171.1 , 161.2, 160.3, 153.5, 151.1 , 149.1, 146.6, 144.5, 143.8, 141.8, 141.7, 127.8, 125.0, 124.1, 123.8, 123.5, 123.2, 122.3, 129.6, 117.6, 117.5, 115.9, 117.7, 1 15.6, 111.4, 111.1, 69.1, 54.8, 54.4, 45.9, 41.9, 27.6. HRMS calculated for
C22H19F5N403S (M + H)+, 515.1171; found, 515.1 181. The intermediate compound j, 2,6-difluoro-3-((6-(trifluoromethyl)thiazolo[5,4-b]pyridin- 2-yl)methoxy)benzamide, was prepared as follows. a. Preparation of Compound j
Figure imgf000021_0001
To 25 mL round bottom flask equipped with a magnetic stirrer, was charged 2- (chloromethyl)-6-(trifluoromethyl) thiazolo [5,4-b] pyridine (350 mg, 1.39 mmol), DMF (2.0 mL), NaHC03 (277 mg, 3.30 mmol), and 2, 6-difluoro-3-hydroxybenzamide (230 mg, 1.32 mmol). The reaction mixture was stirred overnight at 50 °C. The reaction completion was monitored by TLC. After reaction completion, the reaction mixture was cooled to ambient temperature (25-30 °C), water was added and the precipitated material was collected by filtration & dried to give a brown solid. After drying, the crude product was triturated with MDC to afford the desired product as light brown solid in good yield (380 mg, 71% yield). 1H NMR (300 MHz, DMSO-d6) 6: 9.03-9.04 (s, 1H), 8.88-8.89 (s, 1H), 7.35-7.43 (m, 1H), 7.06-7.13 (m, 1H), 5.74 (s, 2H). MS: 390.10 (M+l).
Example 3 Preparation of Representative Salts
Figure imgf000021_0002
Preparation of TXA709. Mesylate: The TXA709 free base was dissolved in THF (1.5L, 7.5 vol) and added Methane sulfonic acid (66g, 686.78 mmol) at 35-40 °C. The contents were stirred for 16h at 25-30 °C, cooled to 0-5 °C and stirred for lh and filtered to give crude as brown solid.
Purification of TXA709 Mesylate: To the solution of crude (TXA709 free base) dissolved in Acetone: Methanol (5.5: 7.0) mixture (2.5L, 12.5 vol) at 55-65 °C, activated carbon (0.5g) was added, stirred for 15 min and filtered through Hy-flo in hot condition. The filtrate was cooled to 25-30 °C, followed by further cooling to 0-5 °C. The contents were stirred for 2h, filtered and dried at 50-55 °C for 8h to give pure product of TXA709. Mesylate as light brown solid. (1 14. Og, 27.89% yield). 1H NMR (300 MHz, DMSO-d6) δ: 1 1.74 (bs, 1H), 9.07 (s, 1H), 8.95 (s, 1H), 7.50-7.58 (m,
1H), 7.17-7.24 (m, 1H), 5.81 (s, 2H), 3.45 - 3.50 (d, 2H), 2.91-3.02 (m, 2H), 2.77-2.84 (d, 4H), 2.31 (s,3H), 2.04 - 2.08 (d, 2H), 1.65-1.77 (m, 2H). MS: 515.08 (M+l).
All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

CLAIMS What is claimed is:
1. A method for preparing a compound of formula (I):
Figure imgf000023_0001
comprising reacting a phenol of formula e
Figure imgf000023_0002
with a chloride of formula h:
Figure imgf000023_0003
to provide the compound of formula (I).
2. The method of claim 1 further comprising preparing the chloride of formula h by reacting the amino pyridine of formula g:
Figure imgf000023_0004
with chloroacetic acid:
O
HO'
to provide the chloride of formula h.
3. The method of claim 2 further comprising preparing the amino pyridine of formula g by converting a corresponding nitro pyridine of formula f:
Figure imgf000024_0001
to the amino pyridine of formula g.
4. The method of claim 3 further comprising preparing a nitro pyridine of formula f by reacting 2-chloro-3-nitro-5-(trifluoromethyl)pyridine with thiourea to provide the nitro pyridine of formula f.
5. The method of any one of claims 1-4 further comprising preparing the phenol of formula e:
Figure imgf000024_0002
by deprotecting the corresponding benzyl ether of formula d:
Figure imgf000024_0003
to provide the phenol of formula e.
6. The method of claim 5 further comprising preparing the benzyl ether of formula d:
Figure imgf000024_0004
by coupling an acid chloride of formula i or a salt thereof:
Figure imgf000025_0001
with an amide of formula c:
Figure imgf000025_0002
to provide the benzyl ether of formula d.
7. The method of claim 6 further comprising preparing the amide of formula c by converting an acid of formula b:
Figure imgf000025_0003
to the amide of formula c.
8. The method of claim 7 further comprising preparing the acid of formula b by converting a compound of formula a:
Figure imgf000025_0004
to the acid of formula b.
9. The method of claim 8 further comprising preparing the compound of formula a by converting a 2,4-difluorophenol to the compound of formula a.
10. A method for preparing a compound of formula (I):
Figure imgf000026_0001
with an acid chloride of formula:
Figure imgf000026_0002
to provide the compound of formula (I).
11. The method of claim 10 further comprising preparing the compound of formula j :
Figure imgf000026_0003
comprising reacting a chloride of formula h:
Figure imgf000026_0004
with a compound of formula:
Figure imgf000027_0001
to provide the compound of formula j.
12. A compound selected from:
Figure imgf000027_0002
and salts thereof.
PCT/US2017/019161 2016-02-25 2017-02-23 Synthetic processes and intermediates WO2017147316A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP17757224.5A EP3419967A4 (en) 2016-02-25 2017-02-23 Synthetic processes and intermediates
US16/079,469 US10513528B2 (en) 2016-02-25 2017-02-23 Synthetic processes and intermediates
JP2018563759A JP2019507801A (en) 2016-02-25 2017-02-23 Synthetic processes and intermediates
CA3015768A CA3015768A1 (en) 2016-02-25 2017-02-23 Synthetic processes and intermediates
CN201780022884.2A CN109195957A (en) 2016-02-25 2017-02-23 Synthetic method and intermediate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641006639 2016-02-25
IN201641006639 2016-02-25

Publications (1)

Publication Number Publication Date
WO2017147316A1 true WO2017147316A1 (en) 2017-08-31

Family

ID=59685558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/019161 WO2017147316A1 (en) 2016-02-25 2017-02-23 Synthetic processes and intermediates

Country Status (6)

Country Link
US (1) US10513528B2 (en)
EP (1) EP3419967A4 (en)
JP (1) JP2019507801A (en)
CN (1) CN109195957A (en)
CA (1) CA3015768A1 (en)
WO (1) WO2017147316A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898317B (en) * 2021-01-21 2021-12-07 河南科技大学第一附属医院 Oxazole compound for sterilization and disinfection in hospital care and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173933A1 (en) * 2006-03-23 2010-07-08 Prolysis Ltd Antibacterial agents
US20120196891A1 (en) * 2009-10-07 2012-08-02 Sumitomo Chemical Company, Limited Heterocyclic compound and its use for control of an arthropod pest
US20150133465A1 (en) * 2013-11-08 2015-05-14 Rutgers, The State University Of New Jersey Antimicrobial agents
US20150307517A1 (en) * 2012-11-08 2015-10-29 Taxis Pharmaceuticals, Inc. Antimicrobial agents

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309539A (en) 1978-03-13 1982-01-05 Hoffmann-La Roche Inc. Pyrimidine derivatives
EP0136745B1 (en) 1983-09-01 1989-06-07 Duphar International Research B.V Benzoyl urea derivatives having anti-tumor activity
US4782058A (en) 1985-04-26 1988-11-01 Pennwalt Corporation 1,3,4,6,7,11b-Hexahydro-6-phenyl-2H-pyrazino-(2,1-a)isoquinolines, for anti-histamine or anti-depression treatment
US5175000A (en) 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5077142A (en) 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
CA2044533A1 (en) 1990-06-29 1991-12-30 Philippe Guerry Substituted aminoalkylbiphenyl derivatives
DE4327748B4 (en) 1993-08-18 2006-07-20 Merck Patent Gmbh Cyclopropyl and cyclobutyl derivatives
FR2728900B1 (en) 1994-12-29 1997-01-31 Synthelabo 3-PHENYLISOQUINOLEIN-1 (2H) -ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JPH11209350A (en) 1998-01-26 1999-08-03 Eisai Co Ltd Nitrogen-containing heterocyclic derivative and medicine containing the same
JP4180723B2 (en) 1999-03-12 2008-11-12 高橋 保 Process for producing pyridines by reaction of azametallacyclopentadiene with alkynes
ES2226839T3 (en) 1999-05-05 2005-04-01 MERCK & CO., INC. NEW CATECOLES AS ANTIMICROBIAL AGENTS.
WO2001087307A2 (en) 2000-05-15 2001-11-22 Celgene Corp. Compositions and methods for the treatment of cancer
EP1324994A4 (en) 2000-10-10 2004-06-16 Calyx Therapeutics Inc Tricyclic compounds and uses thereof
WO2002044127A1 (en) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
MXPA04001773A (en) 2001-08-27 2004-05-31 Arpida Ag 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents.
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
DE60327750D1 (en) 2002-03-18 2009-07-09 Merck Frosst Canada Ltd PDE4 INHIBITORS HAVING HETEROBRESS-SUBSTITUTED 8-ARYLCHINOLINE
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60312520T2 (en) 2002-06-25 2007-11-22 Merck Frosst Canada Ltd., Kirkland 8- (biaryl) quinoline PDE4 INHIBITORS
WO2004005472A2 (en) 2002-07-02 2004-01-15 Southern Research Institute Inhibitors of ftsz and uses thereof
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
GB0303683D0 (en) 2003-02-18 2003-03-19 Prolysis Ltd Antimicrobial agents
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US20050043300A1 (en) 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
AP2321A (en) 2004-01-29 2011-11-16 Janssen Pharmaceutica Nv Quinoline derivatives for use as mycobactrial inhibitor.
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
GB0407861D0 (en) 2004-04-06 2004-05-12 Prolysis Ltd Antibacterial agents
EE05394B1 (en) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Quinoline compounds for use in the treatment of latent tuberculosis
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
RS52010B (en) * 2005-06-22 2012-04-30 Plexxikon Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
GB0605881D0 (en) 2006-03-23 2006-05-03 Prolysis Ltd Antibacterial Agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
US7652151B2 (en) 2006-07-28 2010-01-26 General Electric Company Ketopyrroles useful as ligands in organic iridium compositions
US8045996B2 (en) 2006-07-31 2011-10-25 Qualcomm Incorporated Determination of cell RF parameters based on measurements by user equipments
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
GB0718335D0 (en) 2007-09-20 2007-10-31 Prolysis Ltd Antibacterial agents
GB0718735D0 (en) 2007-09-25 2007-11-07 Prolysis Ltd Antibacterial agents
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
JP5369000B2 (en) 2007-12-25 2013-12-18 キッセイ薬品工業株式会社 Novel catechol derivatives, pharmaceutical compositions containing them, and uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
WO2010127307A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
EP2544528A1 (en) 2010-03-09 2013-01-16 Merck Sharp & Dohme Corp. FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
JP5883591B2 (en) 2010-08-06 2016-03-15 キッセイ薬品工業株式会社 Novel catechol derivatives, pharmaceutical compositions containing them, and uses thereof
CN102070561A (en) * 2010-12-14 2011-05-25 东莞理工学院 Alkyl xanthate-based methylene benzothiazole, and preparation method and application thereof
EP2699557B1 (en) 2011-04-20 2017-08-16 Biota Scientific Management Pty Ltd 3-(oxazol-2-yl-ethoxy)- and 3-(thiazol-2-yl-ethoxy)-benzamide derivatives as anti-bacterial agents
WO2013106761A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173933A1 (en) * 2006-03-23 2010-07-08 Prolysis Ltd Antibacterial agents
US20120196891A1 (en) * 2009-10-07 2012-08-02 Sumitomo Chemical Company, Limited Heterocyclic compound and its use for control of an arthropod pest
US20150307517A1 (en) * 2012-11-08 2015-10-29 Taxis Pharmaceuticals, Inc. Antimicrobial agents
US20150133465A1 (en) * 2013-11-08 2015-05-14 Rutgers, The State University Of New Jersey Antimicrobial agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAUL ET AL.: "Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541 , a 1- methylpiperidine-4-carboxamide prodrug of PC190723", BIOCHEMICAL PHARMACOLOGY, vol. 86, 20 October 2013 (2013-10-20), pages 1699 - 1707, XP028780957 *
KAUL ET AL.: "Supplementary Material - TXA709: A FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, 1 June 2015 (2015-06-01), pages 1 - 9, XP055413331 *
See also references of EP3419967A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
EP3600298A4 (en) * 2017-03-30 2020-11-11 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates

Also Published As

Publication number Publication date
JP2019507801A (en) 2019-03-22
CA3015768A1 (en) 2017-08-31
CN109195957A (en) 2019-01-11
US10513528B2 (en) 2019-12-24
EP3419967A1 (en) 2019-01-02
US20190048024A1 (en) 2019-02-14
EP3419967A4 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
JP6061158B2 (en) Synthesis intermediate of 6- (7-((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide, or a pharmaceutically acceptable salt thereof, and its use
CN107721851B (en) Method for preparing apoptosis inducer
WO2017147316A1 (en) Synthetic processes and intermediates
KR101653025B1 (en) Method for producing 2-amino-4-(trifluoromethyl)pyridine
US20180237386A1 (en) Process For Preparation Of Vortioxetine Hydrobromide
EP2102161B1 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide
WO2016135636A1 (en) Process for the preparation of vortioxetine
CN110891566B (en) Synthesis method and synthesis intermediate
US20220185766A1 (en) Process for the production of substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives
CN111372919B (en) Method for preparing fluopicolide
US20220177417A1 (en) Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
CN109574894B (en) Synthesis method of N- (3- (dimethylamino) -3-propylsulfonyl) -substituted benzamide (I)
TW201313726A (en) Process for manufacturing a synthetic intermediate
US20110166351A1 (en) Method for preparing 5-[2-(methylthio)ethoxy]pyrimidine-2-amine
US20080039613A1 (en) Process for the Production of Azidoalkylamines
US20140275542A1 (en) Synthesis of a serotonin reuptake inhibitor
KR20180093307A (en) Preparing Method of 4,5-diamino substituted pyrimidine derivatives and Novel Compound for Preparing thereof
US20200283389A1 (en) Improved process for making crotonylaminopyridinies

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3015768

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018563759

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017757224

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017757224

Country of ref document: EP

Effective date: 20180925

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17757224

Country of ref document: EP

Kind code of ref document: A1